Ivabradine Aspire

Ivabradine, the active ingredient in Ivabradine Aspire, is a If channel inhibitor presented as an oral tablet for oral use. It selectively lowers heart rate and is indicated for chronic stable angina and certain forms of heart failure in adult patients who remain symptomatic despite optimal therapy.

GNH USA supplies Ivabradine Aspire as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets European Union quality standards and is manufactured under GMP conditions. Our global distribution network ensures reliable delivery to authorized healthcare providers.

Ivabradine acts on the cardiac If current to manage conditions characterized by excessive heart rate.

- Chronic stable angina: reduces frequency of angina attacks and improves exercise tolerance. - Heart failure with reduced ejection fraction: lowers heart rate, decreasing myocardial oxygen demand and may reduce hospitalizations. - Patients with elevated resting heart rate despite beta‑blocker therapy: provides additional heart‑rate control to improve symptoms.

Ivabradine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: resting heart rate below 50 bpm. - Headache. - Dizziness. - Fatigue. - Blurred vision.

Serious or Rare Side Effects: - Symptomatic severe bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Severe hypotension. - Vision loss or persistent visual impairment. - Allergic reactions such as rash, angioedema, or anaphylaxis.

When prescribing Ivabradine, clinicians should observe several safety considerations.

- Heart rate monitoring: check resting heart rate before initiation and periodically thereafter. - Severe hepatic impairment: use with caution or avoid due to altered metabolism. - Sick sinus syndrome or atrioventricular block: contraindicated unless a pacemaker is present. - Concomitant bradycardic agents: avoid combining with other drugs that lower heart rate, such as beta‑blockers or digoxin, without monitoring. - Acute decompensated heart failure: not indicated during unstable phases. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Ivabradine interacts with several medicines that can alter its plasma concentration or additive cardiac effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase ivabradine levels and risk of bradycardia. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy by lowering drug concentrations. - Other bradycardic agents (e.g., digoxin, beta‑blockers, verapamil, diltiazem): can cause severe bradycardia or heart block. - Concomitant use with other If channel inhibitors: not recommended.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): may modestly increase exposure. - Antacids containing aluminum or magnesium: may affect absorption if taken simultaneously. - QT‑prolonging drugs: monitor ECG as combined effect may increase arrhythmia risk.